Pfizer defends Bextra after new report on risks NEW YORK (AFP) - Pfizer dismissed a report on the safety of its pain reliever Bextra, but the new controversy weighed on the stock price of the US pharmaceutical giant. 
Is this a piece of news regarding world politics, sports, business, or science and technology? 